| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Cardinal Health, Inc.$230.03
+2.96 (+1.3%)
D 26Pipeline Score Tools & Services · Commercial
Market Cap
50.72 B
EPS
6.98
P/E Ratio
31.02 $
Value Trade
237.80 M
SEC Financials
Q4 2025Dilution Risk
Revenue
65.63 B
Total Assets
58.08 B
Total Liabilities
58.08 B
Equity
-2.88 B
D/E Ratio
12,345
%
Week
%
1 Month
%
3 Month
%
6 Month
%
5 Year
%
All Time
Cash Data
Cash Position
2.78 B
Monthly Burn
-
Runway
12,345 mo
Burn Trend
StableSEC Filing
Feb 5, 2026
Overview
Volume
1.74 M
52 Week Range
129.52 - 233.60
% held by Insiders
0.25 %
% held by Institutions
89.52 %
Enterprise Value
57.15 B
Total Shares
234.16 M
Short %
2.88 %
Float Shares
233.92 M
Company Description
locked
Upcoming Catalyst
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
2021-05-19 | Lymphoseek Kit (technetium tc-99m tilmanocept) | PDUFA Date | PDUFA | Approved | – | – | – |
2021-05-19 | Lymphoseek Kit (technetium tc-99m tilmanocept) | PDUFA Date | PDUFA | Approved | – | – | – |
2021-05-19 | Lymphoseek Kit (technetium tc-99m tilmanocept) | PDUFA Date | PDUFA | Approved | – | – | – |
Drug Pipeline Intelligence
D26
Pipeline Score $298M
Pipeline ValueValuation Signal
2
Drugs Scored0.0x
rNPV / MCap Top 28%
Large Pharma (rank 658 of 913)
Percentile RankCardinal Health, Inc. faces pipeline headwinds (26/100), with $298M risk-adjusted pipeline value, led by Tc99m tilmanocept in Rhabdomyosarcoma (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tc99m tilmanocept Small molecule | Rhabdomyosarcoma | Phase 2 | NCT02509598 | 10% | $201M | COMPLETED | 24 | - | - | Mar 6, 2019 | - | Jun 28, 2024 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in CAH
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
CAH Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-14 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-14 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-14 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-CAH
Jul 20, 2026Cardinal Health expands home care business with two tuck-in acquisitions
Cardinal Health has announced two acquisitions aimed at expanding its at-Home Solutions business, acquiring the Diabetes Health segment of AdaptHealth and Strive Medical for approximately $360 million. These acquisitions are expected to enhance Cardinal Health's capabilities in diabetes management and urology, building on previous investments in home care. The transactions are pending regulatory approvals and are projected to positively impact earnings in the first year post-acquisition.
Read more →-CAH
Jul 9, 2026Cardinal Health to Announce Fourth-Quarter and Year-End Results for Fiscal Year 2026 on August 11
Cardinal Health plans to announce its fourth-quarter and year-end financial results for fiscal year 2026 on August 11, prior to the NYSE opening. A webcast discussion will follow at 8:30 a.m. Eastern, accessible via the company's Investor Relations page. Presentation materials will be available for a year.
Read more →-CAH
May 5, 2026Cardinal Health Board of Directors Approves Quarterly Dividend
Cardinal Health's Board of Directors has approved a quarterly dividend increase to $0.5158 per share, which will be paid on July 15, 2026. Shareholders of record as of July 1, 2026, will receive this dividend, highlighting the company's ongoing commitment to returning value to its investors. This decision underscores Cardinal Health's financial health and operational success.
Read more →-CAH
Apr 30, 2026Cardinal Health Reports Third Quarter Fiscal Year 2026 Results and Raises Outlook Revenue increased 11% to $60.9 billion GAAP 1 operating earnings decreased 30% to $509 million GAAP diluted EPS decr
Cardinal Health reported a strong third quarter for fiscal 2026 with revenues up 11% to $60.9 billion while non-GAAP operating earnings increased by 18%. However, GAAP operating earnings saw a 30% decline due to a goodwill impairment. The company has raised its non-GAAP EPS guidance for the year, reflecting improved performance in its Pharmaceutical and Specialty Solutions segment. Additionally, Cardinal Health has been active in share repurchases and debt reduction, enhancing its financial stability.
Read more →-CAH
Apr 30, 2026Cardinal Health Reports Third Quarter Fiscal Year 2026 Results and Raises Outlook Cardinal Health (NYSE: CAH) today reported third quarter fiscal year 2026 revenues of $60.9 billion, an increase of 11% from the third quarter of...
Cardinal Health reported a strong third quarter for fiscal year 2026, with revenues of $60.9 billion, marking an 11% increase from the previous year. Despite a significant drop in GAAP operating earnings and diluted EPS due to a goodwill impairment, non-GAAP figures showed improvement, prompting the company to raise its EPS guidance for the fiscal year. The results reflect strong performance in its Pharmaceutical and Specialty Solutions segment.
Read more →-CAH
Apr 14, 2026Cardinal Health report highlights growing momentum to expand advanced therapies into community care settings
Cardinal Health's 2026 Advanced Therapies Report reveals a shift towards administering advanced therapies in community settings. The report highlights strong provider support for these initiatives, emphasizing the importance of partnerships between health systems and community practices. It also notes the operational complexities and planning required to successfully implement these programs, which aim to enhance patient access and experience.
Read more →-CAH
Mar 24, 2026Cardinal Health to Announce Third-Quarter Results for Fiscal Year 2026 on April 30 Cardinal Health (NYSE: CAH) plans to release third-quarter financial results for its fiscal year 2026 on April 30 as previously indicated, prior to...
Cardinal Health plans to release its third-quarter financial results for fiscal year 2026 on April 30. The announcement includes a webcast discussion starting at 8:30 a.m. Eastern. Investors can access the webcast and presentation slides on the company's Investor Relations page.
Read more →-CAH
Feb 5, 2026▲ +9.8%on this news
Cardinal Health Reports Second Quarter Fiscal Year 2026 Results and Raises Outlook Revenue increased 19% to $65.6 billion GAAP 1 operating earnings increased 29% to $707 million GAAP diluted EPS inc
Cardinal Health reported a significant revenue increase of 19% for Q2 FY2026, reaching $65.6 billion, alongside a 29% rise in GAAP operating earnings. The company has raised its fiscal year 2026 non-GAAP EPS guidance to $10.15 to $10.35, reflecting strong segment profit growth. Key contributions were noted in their Pharmaceutical and Specialty Solutions segment, despite challenges such as increased financing costs and adverse tariffs. Overall, the performance exemplifies solid growth across multiple segments and strategic initiatives.
Read more →-CAH
Feb 5, 2026▲ +9.8%on this news
Cardinal Health Reports Second Quarter Fiscal Year 2026 Results and Raises Outlook Cardinal Health (NYSE: CAH) today reported second quarter fiscal year 2026 revenues of $65.6 billion, an increase of 19% from the second quarter of...
Cardinal Health reported strong second quarter results for fiscal year 2026, with revenues of $65.6 billion, marking a 19% increase from the previous year. The company also saw significant growth in both GAAP and non-GAAP operating earnings, leading to a raised EPS guidance for the fiscal year. The CEO highlighted consistent execution across all segments as a key factor in their performance.
Read more →-CAH
Jan 6, 2026Cardinal Health to Announce Second-Quarter Results for Fiscal Year 2026 on February 5 Cardinal Health (NYSE: CAH) plans to release second-quarter financial results for its fiscal year 2026 on February 5, prior to the opening of trading ...
Cardinal Health (NYSE: CAH) will announce its second-quarter financial results for fiscal year 2026 on February 5, before the market opens. A webcast discussion will follow at 8:30 a.m. Eastern, accessible via the Investor Relations page. The company emphasizes its commitment to customer-centric solutions and continuous improvement.
Read more →-CAH
Oct 30, 2025▲ +15.4%on this news
Cardinal Health Reports First Quarter Fiscal Year 2026 Results and Raises Outlook Revenue increased 22% to $64 billion GAAP 1 operating earnings increased 18% to $668 million GAAP diluted EPS increa
Cardinal Health reported strong financial results for the first quarter of fiscal year 2026, showing a 22% increase in revenue to $64 billion and an 18% rise in GAAP operating earnings. The company also raised its fiscal year 2026 EPS guidance, reflecting confidence in continued growth driven by successful operational performance across all segments. Cardinal Health is set to complete the acquisition of Solaris Health in early November, which may further influence its financial trajectory. Overall, the company demonstrates robust growth prospects despite some concerns about increased financing costs.
Read more →-CAH
Sep 23, 2025Cardinal Health to Announce First-Quarter Results for Fiscal Year 2026 on October 30 Cardinal Health (NYSE: CAH) plans to release first-quarter financial results for its fiscal year 2026 on October 30, prior to the opening of trading...
Cardinal Health plans to release its first-quarter financial results for fiscal year 2026 on October 30, before the market opens. A webcast discussion will follow at 8:30 a.m. Eastern, allowing investors to access the information easily. The company highlights its commitment to customer-centric solutions in the healthcare sector.
Read more →-CAH
Aug 12, 2025▼ -7.2%on this news
Cardinal Health Reports Fourth Quarter and Fiscal Year 2025 Results and Raises Fiscal Year 2026 Guidance Fourth quarter revenue was relatively flat at $60.2 billion revenue increased 21% excluding t
Cardinal Health reported its fourth quarter and full year financial results for fiscal year 2025, revealing a flat revenue of $60.2 billion. Despite a decrease in overall revenue for the fiscal year, adjusted non-GAAP operating earnings rose, reflecting strong performance in its Pharmaceutical and Specialty Solutions segments. Additionally, the company announced an increase in non-GAAP EPS guidance for fiscal year 2026 to between $9.30 and $9.50. The company also confirmed its acquisition of Solaris Health, enhancing its multi-specialty service offerings.
Read more →-CAH
Aug 12, 2025▼ -7.2%on this news
Cardinal Health Reports Fourth Quarter and Fiscal Year 2025 Results and Raises Fiscal Year 2026 Guidance Fourth quarter revenue was relatively flat at $60.2 billion; revenue increased 21% excluding the impact of a previously communicated contract...
Cardinal Health reported fourth quarter fiscal year 2025 revenues of $60.2 billion, showing a 21% increase when excluding the impact of a contract expiration. The company raised its fiscal year 2026 non-GAAP EPS guidance to between $9.30 and $9.50. Despite a flat revenue quarter, non-GAAP operating earnings increased by 19% to $719 million, reflecting strong performance across segments.
Read more →-CAH
Jul 15, 2025Cardinal Health to Announce Fourth-Quarter and Year-End Results for Fiscal Year 2025 on August 12 Cardinal Health (NYSE: CAH) plans to release fourth-quarter and year-end financial results for its fiscal year 2025 on August 12, prior to the...
Cardinal Health plans to release its fourth-quarter and year-end financial results for fiscal year 2025 on August 12, before the market opens. A webcast discussion will follow at 8:30 a.m. Eastern, accessible via the Investor Relations page. Presentation materials will be available for a year.
Read more →-CAH
Jun 12, 2025Cardinal Health Details Momentum and Updated Long-Term Value Creation Plans at Investor Day Key announcements: Raising FY25 non-GAAP diluted EPS guidance to $8.15 to $8.201 Establishing preliminary FY26 non-GAAP diluted EPS guidance of $9.10 ...
Cardinal Health hosted an Investor Day where it announced updates to its financial guidance, including an increase in FY25 non-GAAP diluted EPS guidance and preliminary guidance for FY26. The company confirmed long-term growth targets and outlined strategic priorities in various sectors, including Pharmaceutical and Specialty Solutions. Cardinal Health expects significant cash flow generation and plans for substantial share repurchases.
Read more →-CAH
May 1, 2025Cardinal Health Reports Third Quarter Fiscal Year 2025 Results and Raises Fiscal Year 2025 Outlook Revenue was flat at $54.9 billion revenue increased 19% excluding the impact of the previously comm
Cardinal Health announced its third quarter fiscal year 2025 results, reporting flat revenue at $54.9 billion while increasing its non-GAAP EPS guidance for the year to $8.05 to $8.15. The company witnessed a 21% increase in non-GAAP operating earnings, attributed to segment profit growth across all operating areas. Additionally, GI Alliance expanded into the urology therapeutic area and completed its acquisition of Advanced Diabetes Supply Group. Despite challenges, the company remains optimistic about future growth and innovation.
Read more →-CAH
Mar 25, 2025Cardinal Health to Announce Third-Quarter Results for Fiscal Year 2025 on May 1 Cardinal Health (NYSE: CAH) plans to release third-quarter financial results for its fiscal year 2025 on May 1, prior to the opening of trading on...
Cardinal Health (NYSE: CAH) will announce its third-quarter financial results for fiscal year 2025 on May 1, before the market opens. A webcast discussion will follow at 8:30 a.m. Eastern, accessible via the Investor Relations page. Presentation materials will be available for 12 months.
Read more →-CAH
Mar 10, 2025Robert Musslewhite and Sudhakar Ramakrishna to join Cardinal Health Board of Directors
Cardinal Health has appointed Robert Musslewhite and Sudhakar Ramakrishna as independent directors to its Board of Directors, effective March 7, 2025. Musslewhite, with extensive experience in healthcare technology, and Ramakrishna, a technology leader, are expected to provide valuable insights and expertise in navigating complex business challenges. Both bring over two decades of leadership experience and a history of success in their respective fields, which aligns with Cardinal Health's strategic goals.
Read more →-CAH
Jan 30, 2025Cardinal Health Reports Second Quarter Fiscal Year 2025 Results and Raises Fiscal Year 2025 Outlook Revenue decreased 4% to $55.3 billion revenue increased 16% excluding the impact of the previously
Cardinal Health reported a 4% decrease in Q2 FY2025 revenue, totaling $55.3 billion, but noted a 16% increase when excluding the impact of a significant customer contract expiration. The company achieved a 9% rise in GAAP operating earnings and also raised its non-GAAP EPS guidance for the fiscal year. Additionally, Cardinal Health completed its acquisition of a majority stake in GI Alliance, which is expected to enhance its growth strategy in specialty solutions. The company continues to navigate challenges such as revenue declines from the contractual loss.
Read more →-CAH
Dec 19, 2024Cardinal Health to Announce Second-Quarter Results for Fiscal Year 2025 on January 30 Cardinal Health (NYSE: CAH) plans to release second-quarter financial results for its fiscal year 2025 on January 30, prior to the opening of trading ...
Cardinal Health will announce its second-quarter financial results for fiscal year 2025 on January 30, 2025, before the market opens. A webcast discussion will follow at 8:30 a.m. Eastern, accessible via the company's Investor Relations page. Presentation materials will be available for 12 months.
Read more →-CAH
Nov 11, 2024Cardinal Health announces two strategic additions to its portfolio Acquisition of a majority stake in GI Alliance, the country s leading gastroenterology management services organization, to accelerate Cardinal Health s
Cardinal Health has announced the acquisition of a majority stake in GI Alliance and Advanced Diabetes Supply Group, totaling approximately $3.9 billion. These acquisitions are aimed at enhancing its specialty services and at-home care capabilities, positioning the company for growth in key healthcare areas. The transactions are expected to close in early 2025 and will include approximately 71% ownership of GI Alliance and a merger with Cardinal Health's at-Home Solutions business. The company reaffirms its commitment to disciplined capital allocation and anticipates positive contributions from both acquisitions to revenue and profits within the first year post-completion.
Read more →-CAH
Nov 1, 2024▲ +7%on this news
Cardinal Health Reports First Quarter Fiscal Year 2025 Results and Raises Fiscal Year 2025 Outlook Revenue decreased 4% to $52.3 billion revenue increased 15% excluding the impact of the previously
Cardinal Health reported its first quarter fiscal year 2025 results, noting a revenue decrease of 4% to $52.3 billion, though adjusted earnings showed positive growth. Excluding the impact of a large customer contract expiration, revenue increased by 15%. The company raised its fiscal year 2025 non-GAAP EPS guidance to a range of $7.75 to $7.90, driven primarily by growth in its Pharmaceutical and Specialty Solutions segment. Other segments exhibited mixed results, with some efficiencies in costs yet challenges in revenue from specific sectors.
Read more →-CAH
Nov 1, 2024▲ +7%on this news
Cardinal Health Reports First Quarter Fiscal Year 2025 Results and Raises Fiscal Year 2025 Outlook Cardinal Health (NYSE: CAH) today reported first quarter fiscal year 2025 revenue of $52.3 billion, a decrease of 4% from the first quarter of fiscal ...
Cardinal Health reported a first quarter fiscal year 2025 revenue of $52.3 billion, reflecting a 4% decrease from the previous year. However, excluding the impact of a large customer contract expiration, revenue increased by 15%. The company raised its fiscal 2025 non-GAAP EPS guidance to between $7.75 and $7.90, driven by strong performance in its Pharmaceutical and Specialty Solutions segment. Despite the overall revenue decline, the company is optimistic about its financial outlook.
Read more →-CAH
Sep 24, 2024Cardinal Health to Announce First-Quarter Results for Fiscal Year 2025 on November 1 Cardinal Health (NYSE: CAH) plans to release first-quarter financial results for its fiscal year 2025 on November 1, prior to the opening of trading...
Cardinal Health (NYSE: CAH) will announce its first-quarter financial results for fiscal year 2025 on November 1, before the market opens. A webcast discussion will follow at 8:30 a.m. Eastern, providing insights into the company's performance. The presentation will be accessible on their Investor Relations page for a year.
Read more →-CAH
Aug 14, 2024Cardinal Health Reports Fourth Quarter and Fiscal Year 2024 Results and Raises Fiscal Year 2025 Guidance Cardinal Health (NYSE: CAH) today reported fourth quarter fiscal year 2024 revenues of $59.9 billion, an increase of 12% from the prior year. GAAP...
Cardinal Health reported strong financial results for the fourth quarter and fiscal year 2024, with revenues reaching $59.9 billion, a 12% increase year-over-year. The company also raised its fiscal year 2025 guidance for non-GAAP EPS to between $7.55 and $7.70. Key drivers of growth included increases in segment profits from Global Medical Products and Distribution and Pharmaceutical and Specialty Solutions. The CEO highlighted robust cash flow generation and strategic progress in the company's portfolio.
Read more →-CAH
Aug 14, 2024Cardinal Health Reports Fourth Quarter and Fiscal Year 2024 Results and Raises Fiscal Year 2025 Guidance Fourth quarter revenue increased 12% to $59.9 billion Fourth quarter GAAP 1 operating earning
Cardinal Health reported strong financial results for the fourth quarter and fiscal year 2024, with revenues reaching $59.9 billion, reflecting a 12% increase from the previous year. The company also achieved significant increases in earnings per share, both on GAAP and non-GAAP bases, signaling robust operational execution and strategic progress. Fiscal Year 2025 guidance has been positively revised, indicating confidence in continued financial growth. Key segments contributing to this success include Pharmaceutical and Specialty Solutions, as well as Global Medical Products and Distribution.
Read more →-CAH
Jul 23, 2024Cardinal Health to Announce Fourth-Quarter and Year-End Results for Fiscal Year 2024 on August 14 Cardinal Health (NYSE: CAH) plans to release fourth-quarter and year-end financial results for its fiscal year 2024 on August 14, prior to the...
Cardinal Health will announce its fourth-quarter and year-end financial results for fiscal year 2024 on August 14, before the market opens. A webcast discussion will follow at 8:30 a.m. Eastern, with access available via the Investor Relations page. The company has a significant global presence and a long history in the healthcare sector.
Read more →-CAH
May 2, 2024Cardinal Health Reports Third Quarter Fiscal Year 2024 Results and Raises Fiscal Year 2024 Non-GAAP EPS Guidance Cardinal Health (NYSE: CAH) today reported third quarter fiscal year 2024 revenues of $54.9 billion, an increase of 9% from the third quarter of...
Cardinal Health reported a 9% increase in third quarter fiscal year 2024 revenues, reaching $54.9 billion. The company raised its non-GAAP EPS guidance for the fiscal year to between $7.30 and $7.40, reflecting strong performance in its Pharmaceutical and Specialty Solutions segment. However, GAAP operating earnings saw a significant decline due to a goodwill impairment charge.
Read more →-CAH
May 2, 2024Cardinal Health Reports Third Quarter Fiscal Year 2024 Results and Raises Fiscal Year 2024 Non-GAAP EPS Guidance Revenue increased 9% to $54.9 billion GAAP 1 operating earnings were $367 million GAA
Cardinal Health reported its third quarter fiscal year 2024 results, revealing a revenue increase of 9% to $54.9 billion. Non-GAAP diluted EPS also rose, reflecting strong performance in their Pharmaceutical and Specialty Solutions segments. The company raised its fiscal year 2024 non-GAAP EPS guidance, indicating a positive outlook for future performance. However, GAAP operating earnings and net earnings saw declines, primarily affected by a significant goodwill impairment.
Read more →-CAH
Apr 23, 2024Cardinal Health, Inc. and Subsidiaries Segment Information Fiscal Year 2022 Fiscal Year 2023 Fiscal Year 2024 (in millions) Q1 Q2 Q3 Q4 Full Year Q1 Q2 Q3 Q4 Full Year Q1 Q2 YTD Segment Revenue Pharmaceutical and Special
Cardinal Health, Inc. reported their segment information for fiscal years 2022, 2023, and 2024, showcasing robust revenue growth in the Pharmaceutical and Specialty Solutions segment. The total segment revenue grew, while the Pharmaceutical segment profit demonstrated resilience with an increase from the previous fiscal year. However, the Global Medical Products and Distribution segment suffered considerable losses, reflecting challenges within that area. Overall, while Cardinal Health shows strong metrics in certain segments, there are specific areas, particularly in medical products, that are underperforming.
Read more →-CAH
Apr 22, 2024Cardinal Health Reaffirms Fiscal 2024 non-GAAP EPS Guidance and Long-term Targets Amidst Nonrenewal of OptumRx Customer Contracts
Cardinal Health announced that it will not renew its pharmaceutical distribution contracts with OptumRx, which comprised 16% of its consolidated revenue in fiscal 2023. Despite this setback, the company reaffirmed its fiscal 2024 non-GAAP EPS guidance of $7.20 to $7.35 and its long-term growth targets. Management remains optimistic about achieving sustained growth by onboarding new customers and capitalizing on opportunities in the market. Adjusted free cash flow expectations are lower for fiscal 2025, reflecting challenges associated with the OptumRx contract.
Read more →-CAH
Mar 26, 2024Cardinal Health to Announce Third-Quarter Results for Fiscal Year 2024 on May 2 Cardinal Health (NYSE: CAH) plans to release third-quarter financial results for its fiscal year 2024 on May 2, prior to the opening of trading on...
Cardinal Health will release its third-quarter financial results for fiscal year 2024 on May 2, before the market opens. A webcast discussion will follow at 8:30 a.m. Eastern, accessible via the company's Investor Relations page. This event showcases Cardinal Health's commitment to transparency and investor engagement.
Read more →-CAH
Feb 28, 2024Bob Azelby to join Cardinal Health Board of Directors
Cardinal Health announced the election of Robert 'Bob' Azelby as an independent director on its Board of Directors, effective March 1, 2024. Azelby has over 30 years of experience in the healthcare industry, holding leadership positions at various biopharmaceutical organizations. His extensive background in oncology and specialty pharmaceuticals is expected to provide significant value to the company as it pursues its strategic priorities. The board's chairman highlighted Azelby's strong track record, indicating confidence in his ability to contribute meaningfully to the company's future.
Read more →-CAH
Feb 1, 2024Cardinal Health Reports Second Quarter Fiscal 2024 Results and Raises Fiscal 2024 Outlook Revenue increased 12% to $57.4 billion GAAP1 operating earnings were $482 million; GAAP diluted EPS was $1.43 Non-GAAP operating earnings increased...
Cardinal Health reported a strong second quarter for fiscal 2024, with revenue reaching $57.4 billion, a 12% increase year-over-year. The company raised its non-GAAP EPS guidance for the fiscal year to between $7.20 and $7.35, reflecting robust growth in both its Pharmaceutical and Medical segments. However, the effective tax rate saw a significant rise, impacting overall earnings.
Read more →-CAH
Feb 1, 2024Cardinal Health Reports Second Quarter Fiscal 2024 Results and Raises Fiscal 2024 Outlook Revenue increased 12% to $57.4 billion GAAP 1 operating earnings were $482 million GAAP diluted EPS was $1.4
Cardinal Health (CAH) reported strong financial results for the second quarter of fiscal 2024, with revenue rising 12% to $57.4 billion and a notable increase in both GAAP and non-GAAP earnings metrics. The company raised its full-year guidance for non-GAAP EPS to between $7.20 and $7.35, driven by solid growth in its Pharmaceutical segment, which saw increased profits and sales from brand and specialty products. The firm also announced plans for a new acquisition and investments in its at-Home Solutions business, further emphasizing its commitment to operational improvements and shareholder value.
Read more →-CAH
Jan 9, 2024Cardinal Health Announces Progress on Business and Portfolio Review and Fiscal 2024 Outlook Update Progress achieved on company's ongoing business and portfolio review Completed review of growth businesses within the Medical Segment: investing in...
Cardinal Health has announced significant progress in its business and portfolio review, focusing on long-term growth through investments in at-Home Solutions and OptiFreight logistics. The company has updated its fiscal 2024 non-GAAP diluted EPS guidance to a higher range, driven by strong cash flow and share repurchases. An updated operating and segment reporting structure will take effect on January 1, 2024, enhancing visibility and operational efficiency.
Read more →-CAH
Jan 2, 2024Cardinal Health to Announce Second-Quarter Results for Fiscal Year 2024 on February 1 Cardinal Health (NYSE: CAH) plans to release second-quarter financial results for its fiscal year 2024 on February 1, prior to the opening of trading ...
Cardinal Health will release its second-quarter financial results for fiscal year 2024 on February 1, 2024, before the market opens. A webcast discussing these results will start at 8:30 a.m. Eastern time. The presentation will be available for 12 months on the company's Investor Relations page.
Read more →-CAH
Jan 1, 2024Cardinal Health Announces Progress on Business and Portfolio Review and Fiscal 2024 Outlook Update Progress achieved on company's ongoing business and portfolio review o Completed review of growth businesses within the M
Cardinal Health (CAH) announced significant progress in its business and portfolio review, highlighting completed evaluations of its growth businesses in the Medical Segment. The company has revised its fiscal 2024 non-GAAP diluted EPS guidance to reflect positive cash flow and increased efficiencies. Additionally, Cardinal Health has initiated an updated enterprise operating structure, aimed at streamlining operations and enhancing focus on core segments, effective January 1, 2024. Future financial targets reflect an optimistic long-term growth projection of 12% to 14% in diluted EPS.
Read more →-CAH
Nov 3, 2023▲ +6.9%on this news
Cardinal Health Reports First Quarter Fiscal 2024 Results and Raises Fiscal 2024 Outlook Revenue increased 10% to $54.8 billion GAAP 1 operating loss was $14 million and GAAP diluted EPS was $0.02,
Cardinal Health reported a 10% increase in revenue for Q1 fiscal 2024, reaching $54.8 billion, despite a GAAP operating loss of $14 million attributed to a goodwill impairment in the Medical segment. Non-GAAP operating earnings rose significantly by 35%, while non-GAAP diluted EPS was up by 44%. The company has raised its EPS guidance for the fiscal year, reflecting optimism about growth in both the Pharmaceutical and Medical segments. However, the Medical segment's revenue remained stagnant, which could pose concerns for future growth.
Read more →-CAH
Aug 15, 2023Cardinal Health Reports Fourth Quarter and Full Year Results for Fiscal Year 2023 at High End of Investor Day Guidance Fourth quarter revenue increased 13% to $53.5 billion Fourth quarter GAAP 1 ope
Cardinal Health reported its fourth quarter and full year results for fiscal year 2023, highlighting a revenue increase of 13% to $53.5 billion. The company's non-GAAP diluted earnings per share rose significantly by 48% to $1.55. However, GAAP diluted loss per share was reported at $0.25, primarily due to a substantial goodwill impairment charge. Looking ahead, Cardinal Health has raised its fiscal year 2024 non-GAAP EPS guidance to a range of $6.50 to $6.75, driven by solid performance in both the Pharmaceutical and Medical segments.
Read more →-CAH
Jun 8, 2023Cardinal Health Investor Day to Highlight Long-Term Value Creation Narrowing fiscal year 2023 non-GAAP diluted EPS guidance to $5.65 to $5.80, from $5.60 to $5.80 (13% growth at the mid-point) 1 Providing preliminary fis
Cardinal Health recently hosted an Investor Day, where the company provided updates on its fiscal guidance and strategic initiatives. The firm narrowed its fiscal year 2023 non-GAAP diluted EPS guidance to $5.65 to $5.80 and projected a preliminary EPS guidance of $6.45 to $6.70 for fiscal year 2024, reflecting expected growth. Additionally, Cardinal Health announced a new $3.5 billion share repurchase authorization and outlined long-term financial targets indicating growth in the Pharmaceutical segment. The investor presentation emphasized the company's commitment to simplifying operations and driving growth in strategic areas.
Read more →-CAH
May 4, 2023Cardinal Health Reports Third Quarter Fiscal Year 2023 Results and Raises Fiscal Year 2023 Non-GAAP EPS Guidance Revenue increased 13% to $50.5 billion GAAP 1 operating earnings were $572 million; G
Cardinal Health has reported a strong financial performance for the third quarter of fiscal year 2023, with revenues reaching $50.5 billion, marking a 13% increase year-over-year. The company achieved a significant rise in non-GAAP diluted earnings per share, which rose 20% to $1.74, prompting a raise in the full-year guidance. However, challenges remain in the Medical segment, which saw a substantial decline in profit due to lower sales and pricing pressures. The firm continues to express confidence in its Pharmaceutical segment performance despite the mixed results across its divisions.
Read more →-CAH
Feb 2, 2023Cardinal Health Reports Second Quarter Fiscal Year 2023 Results and Raises Fiscal Year 2023 Non-GAAP EPS Guidance Revenue increased 13% to $51.5 billion GAAP 1 operating loss was $119 million due to
Cardinal Health reported $51.5 billion in revenue for Q2 FY2023, a 13% increase from the previous year. Despite a GAAP operating loss of $119 million caused by a goodwill impairment, the company raised its non-GAAP earnings per share guidance. Non-GAAP diluted EPS rose 4% to $1.32, driven primarily by lower interest expenses and share count. The company expressed confidence in their plans to improve performance in the Medical segment while highlighting significant growth in Pharmaceuticals.
Read more →-CAH
Nov 4, 2022▲ +5.1%on this news
Cardinal Health Reports First Quarter Fiscal 2023 Results Revenue increased 13% to $49.6 billion GAAP 1 operating earnings were $137 million, GAAP diluted EPS were $0.40 Non-GAAP operating earnings
Cardinal Health Reports First Quarter Fiscal 2023 Results Revenue increased 13% to $49.6 billion GAAP1 operating earnings were $137 million, GAAP diluted EPS were $0.40 Non-GAAP operating earnings decreased 20% to $423 million due to a decline in Medical segment profit, partia
Read more →-CAH
Sep 8, 2022Cardinal Health Announces Pharmaceutical Segment Organizational Changes --Victor Crawford will step down as CEO of Pharmaceutical Segment-- --Debbie Weitzman, President of Pharmaceutical Distribution, named CEO of Pharma
EX-99.1 2 exhibit991-sept2022form8xk.htm EX-99.1 Document Exhibit 99.1 Cardinal Health Announces Pharmaceutical Segment Organizational Changes --Victor Crawford will step down as CEO of Pharmaceutical Segment-- --Debbie Weitzman, President of Pharmaceutical Distribution, named CE
Read more →-CAH
Sep 6, 2022Cardinal Health Announces Governance Enhancements and Shareholder Value Creation Initiatives Adds Four New Independent Directors to the Board Forms New Business Review Committee to Evaluate Portfolio and Operations
EX-99.1 3 exhibit99-1pressrelease.htm EXHIBIT 99.1 Cardinal Health Announces Governance Enhancements and Shareholder Value Creation Initiatives Adds Four New Independent Directors to the Board Forms New Business Review Committee to Evaluate Portfolio and Operations DUBLIN, Ohio,
Read more →-CAH
Aug 11, 2022▲ +5.2%on this news
Cardinal Health Reports Fourth Quarter and Full Year Results for Fiscal Year 2022 Revenue increased 11% to $47.1 billion in the fourth quarter GAAP 1 operating earnings were $36 million in the fourt
Cardinal Health Reports Fourth Quarter and Full Year Results for Fiscal Year 2022 Revenue increased 11% to $47.1 billion in the fourth quarter GAAP1 operating earnings were $36 million in the fourth quarter GAAP diluted EPS were $0.50 in the fourth quarter Non-GAAP operating e
Read more →-CAH
Jul 22, 2022UNITED STATES DISTRICT COURT FOR THE SOUTHERN DISTRICT OF OHIO EASTERN DIVISION IN RE CARDINAL HEALTH, INC. DERIVATIVE LITIGATION Case No. 2 19-cv-2491 Judge Sarah D. Morrison Magistrate Judge Elizabeth A. Preston Deaver
UNITED STATES DISTRICT COURT FOR THE SOUTHERN DISTRICT OF OHIO STIPULATION AND AGREEMENT OF COMPROMISE, SETTLEMENT, AND RELEASE This Stipulation and Agreement of Compromise, Settlement, and Release (the "Stipulation") is entered into this 25th day of Mayl, 2022, by and among (
Read more →-CAH
May 5, 2022Cardinal Health Reports Third Quarter Fiscal 2022 Results Revenue increased 14% to $44.8 billion GAAP 1 operating loss was $97 million due to a non-cash, pre-tax goodwill impairment of $474 million
Cardinal Health Reports Third Quarter Fiscal 2022 Results Revenue increased 14% to $44.8 billion GAAP1 operating loss was $97 million due to a non-cash, pre-tax goodwill impairment of $474 million in the Medical segment GAAP diluted loss per share was $5.05, primarily due to th
Read more →-CAH
Feb 3, 2022Cardinal Health Reports Second Quarter Fiscal 2022 Results Revenue increased 9% to $45.5 billion GAAP 1 operating loss was $950 million due to a non-cash, pre-tax goodwill impairment of $1.3 billion
Cardinal Health Reports Second Quarter Fiscal 2022 Results Revenue increased 9% to $45.5 billion GAAP1 operating loss was $950 million due to a non-cash, pre-tax goodwill impairment of $1.3 billion related to the Medical segment GAAP diluted earnings per share were $0.17 Non-G
Read more →-CAH
Nov 9, 2021Cardinal Health Reports First Quarter Fiscal 2022 Results Revenue increased 13% to $44.0 billion GAAP 1 operating earnings were $415 million, GAAP diluted EPS were $0.94 Non-GAAP operating earnings
Cardinal Health Reports First Quarter Fiscal 2022 Results Revenue increased 13% to $44.0 billion GAAP1 operating earnings were $415 million, GAAP diluted EPS were $0.94 Non-GAAP operating earnings decreased 15% to $527 million, non-GAAP diluted EPS decreased 15% to $1.29 Boar
Read more →-CAH
Aug 5, 2021▼ -14.3%on this news
Cardinal Health reports fourth quarter and full year results for fiscal year 2021 Revenue increased 16% to $42.6 billion in the fourth quarter GAAP 1 operating earnings decreased 40% to $162 million
Cardinal Health reports fourth quarter and full year results for fiscal year 2021 Revenue increased 16% to $42.6 billion in the fourth quarter GAAP1 operating earnings decreased 40% to $162 million and non-GAAP operating earnings decreased 28% to $320 million in the fourth quar
Read more →-CAH
Jul 22, 2021DISTRIBUTORS ANNOUNCE PROPOSED OPIOID SETTLEMENT AGREEMENT 07/21/2021 CONSHOHOCKEN, Pa. & DUBLIN, Ohio & IRVING, Texas -- AmerisourceBergen (NYSE: ABC), Cardinal Health (NYSE: CAH) and McKesson (NYSE: MCK) announced toda
DISTRIBUTORS ANNOUNCE PROPOSED OPIOID SETTLEMENT AGREEMENT CONSHOHOCKEN, Pa. & DUBLIN, Ohio & IRVING, Texas -- AmerisourceBergen (NYSE: ABC), Cardinal Health (NYSE: CAH) and McKesson (NYSE: MCK) announced today that they have negotiated a comprehensive proposed settlement agreem
Read more →-CAH
May 6, 2021Cardinal Health reports third-quarter results for fiscal year 2021 Revenue was flat at $39.3 billion GAAP 1 operating earnings decreased to $473 million, GAAP diluted EPS decreased to $0.40 Non-GAAP
Cardinal Health reports third-quarter results for fiscal year 2021 Revenue was flat at $39.3 billion GAAP1 operating earnings decreased to $473 million, GAAP diluted EPS decreased to $0.40 Non-GAAP operating earnings decreased 4% to $689 million, non-GAAP diluted EPS decreased
Read more →-CAH
Mar 12, 2021Cardinal Health signs definitive agreement to sell its Cordis business to Hellman Friedman Cordis business to be sold to Hellman Friedman (H F) for approximately $1 billion, which includes buyer's assumption of certain l
EX-99.2 3 a21q3_x031021xex992xnewsre.htm EX-99.2 Document Exhibit 99.2 Cardinal Health signs definitive agreement to sell its Cordis business to Hellman Friedman Cordis business to be sold to Hellman Friedman (H F) for approximately $1 billion, which includes buyer's assumption o
Read more →-CAH
Feb 5, 2021Cardinal Health Reports Second-Quarter Results for Fiscal Year 2021 Revenue increased 5% to $41.5 billion GAAP 1 operating earnings were $461 million, GAAP diluted EPS were $2.13 Non-GAAP operating
Cardinal Health Reports Second-Quarter Results for Fiscal Year 2021 Revenue increased 5% to $41.5 billion GAAP1 operating earnings were $461 million, GAAP diluted EPS were $2.13 Non-GAAP operating earnings decreased 3% to $628 million, non-GAAP diluted EPS increased 14% to $1.
Read more →-CAH
Nov 5, 2020Cardinal Health Reports First Quarter Fiscal 2021 Results Revenue increased 5% to $39.1 billion GAAP 1 operating loss was $624 million due to an incremental $1.0 billion pre-tax accrual related to o
Cardinal Health Reports First Quarter Fiscal 2021 Results Revenue increased 5% to $39.1 billion GAAP1 operating loss was $624 million due to an incremental $1.0 billion pre-tax accrual related to opioid litigation non-GAAP operating earnings increased 7% to $618 million GAAP d
Read more →-CAH
Aug 31, 2020Media: Sarah Shew Investors: Kevin Moran (614) 553.3401 (614) 757-7942 Sarah.Shew@cardinalhealth.com Kevin.Moran@cardinalhealth.com Sheri Edison to join Cardinal Health Board of Directors DUBLIN, OH
Media: Sarah Shew Investors: Kevin Moran (614) 553.3401 (614) 757-7942 Sarah.Shew@cardinalhealth.com Kevin.Moran@cardinalhealth.com Sheri Edison to join Cardinal Health Board of Directors DUBLIN, OHIO - August 31, 2020 - Cardinal Health (NYSE: CAH) announced today that i
Read more →-CAH
Aug 6, 2020Media: Sarah Shew Investors: Kevin Moran (614) 553-3401 (614) 757-7942 Sarah.Shew@cardinalhealth.com Kevin.Moran@cardinalhealth.com Cardinal Health Reports Fourth Quarter and Full Year Results for F
Media: Sarah Shew Investors: Kevin Moran (614) 553-3401 (614) 757-7942 Sarah.Shew@cardinalhealth.com Kevin.Moran@cardinalhealth.com Cardinal Health Reports Fourth Quarter and Full Year Results for Fiscal Year 2020 Fourth quarter fiscal 2020 results: Full year fiscal 202
Read more →-CAH
May 11, 2020Media: Sarah Shew Investors: Kevin Moran (614) 553-3401 (614) 757-7942 Sarah.Shew@cardinalhealth.com Kevin.Moran@cardinalhealth.com Cardinal Health Reports Third Quarter Results for Fiscal Year 2020
Media: Sarah Shew Investors: Kevin Moran (614) 553-3401 (614) 757-7942 Sarah.Shew@cardinalhealth.com Kevin.Moran@cardinalhealth.com Cardinal Health Reports Third Quarter Results for Fiscal Year 2020 DUBLIN, Ohio, May 11, 2020 - Cardinal Health (NYSE: CAH) today reported
Read more →-CAH
Mar 19, 2020Media: Erica Lewis Investors: Kevin Moran (614) 787-0087 (614) 757-7924 Erica.Lewis@cardinalhealth.com Kevin.Moran@cardinalhealth.com Cardinal Health names Jason Hollar as new Chief Financial Office
Media: Erica Lewis Investors: Kevin Moran (614) 787-0087 (614) 757-7924 Erica.Lewis@cardinalhealth.com Kevin.Moran@cardinalhealth.com Cardinal Health names Jason Hollar as new Chief Financial Officer DUBLIN, Ohio, March 19, 2020 -- Cardinal Health (NYSE: CAH) announced t
Read more →-CAH
Feb 6, 2020Media: Erica Lewis Investors: Kevin Moran (614) 787-0087 (614) 757-7942 Erica.Lewis@cardinalhealth.com Kevin.Moran@cardinalhealth.com Cardinal Health Reports Second Quarter Results for Fiscal Year 2
Media: Erica Lewis Investors: Kevin Moran (614) 787-0087 (614) 757-7942 Erica.Lewis@cardinalhealth.com Kevin.Moran@cardinalhealth.com Cardinal Health Reports Second Quarter Results for Fiscal Year 2020 DUBLIN, Ohio, February 6, 2020 - Cardinal Health (NYSE: CAH) today re
Read more →-CAH
Jan 30, 2020Media: Erica Lewis (614) 787-0087 erica.lewis@cardinalhealth.com Investors: Kevin Moran (614) 757-7942 kevin.moran@cardinalhealth.com Cardinal Health announces voluntary field actions for select procedure packs containin
Cardinal Health announces voluntary field actions for select procedure packs containing affected surgical gowns DUBLIN, Ohio, January 30, 2020 - Today, in continued coordination with the U.S. Food and Drug Administration (FDA), Cardinal Health announced it is initiating two volu
Read more →-CAH
Nov 7, 2019Media: Brandi Martin Investors: Kevin Moran (614) 757-3383 (614) 757-7942 Brandi.Martin@cardinalhealth.com Kevin.Moran@cardinalhealth.com Cardinal Health Reports First Quarter Results for Fiscal Yea
Media: Brandi Martin Investors: Kevin Moran (614) 757-3383 (614) 757-7942 Brandi.Martin@cardinalhealth.com Kevin.Moran@cardinalhealth.com Cardinal Health Reports First Quarter Results for Fiscal Year 2020 DUBLIN, Ohio, November 7, 2019 - Cardinal Health (NYSE: CAH) today
Read more →-CAH
Aug 8, 2019Media: Brandi Martin Investors: Lisa Capodici (614) 757-3383 (614) 757-5035 brandi.martin@cardinalhealth.com lisa.capodici@cardinalhealth.com Cardinal Health Reports Fourth Quarter and Full Year Res
Media: Brandi Martin Investors: Lisa Capodici (614) 757-3383 (614) 757-5035 brandi.martin@cardinalhealth.com lisa.capodici@cardinalhealth.com Cardinal Health Reports Fourth Quarter and Full Year Results for Fiscal Year 2019 DUBLIN, Ohio, August 8, 2019 - Cardinal Health
Read more →-CAH
Jul 16, 2019Media: Brandi Martin Investors: Lisa Capodici (614) 757-3383 (614) 757-5035 brandi.martin@cardinalhealth.com lisa.capodici@cardinalhealth.com CARDINAL HEALTH APPOINTS STEPHEN MASON TO LEAD MEDICAL S
Media: Brandi Martin Investors: Lisa Capodici (614) 757-3383 (614) 757-5035 brandi.martin@cardinalhealth.com lisa.capodici@cardinalhealth.com CARDINAL HEALTH APPOINTS STEPHEN MASON TO LEAD MEDICAL SEGMENT Company Expects to Meet at Least the Midpoint of its Previously A
Read more →-CAH
May 9, 2019Media: Brandi Martin Investors: Lisa Capodici (614) 757-3383 (614) 757-5035 brandi.martin@cardinalhealth.com lisa.capodici@cardinalhealth.com Cardinal Health Reports Third Quarter Results for Fiscal
Media: Brandi Martin Investors: Lisa Capodici (614) 757-3383 (614) 757-5035 brandi.martin@cardinalhealth.com lisa.capodici@cardinalhealth.com Cardinal Health Reports Third Quarter Results for Fiscal Year 2019 DUBLIN, Ohio, May 9, 2019 - Cardinal Health (NYSE: CAH) today
Read more →-CAH
Feb 7, 2019Media: Brandi Martin Investors: Lisa Capodici (614) 757-3383 (614) 757-5035 brandi.martin@cardinalhealth.com lisa.capodici@cardinalhealth.com Cardinal Health Reports Second Quarter Results for Fisca
Media: Brandi Martin Investors: Lisa Capodici (614) 757-3383 (614) 757-5035 brandi.martin@cardinalhealth.com lisa.capodici@cardinalhealth.com Cardinal Health Reports Second Quarter Results for Fiscal Year 2019 DUBLIN, Ohio, February 7, 2019 - Cardinal Health (NYSE: CAH)
Read more →-CAH
Dec 7, 2018Media: Ellen Barry Investors: Lisa Capodici (614) 553-3858 (614) 757-5035 ellen.barry@cardinalhealth.com lisa.capodici@cardinalhealth.com Cardinal Health Elects J. Michael Losh to its Board of Directors
Media: Ellen Barry Investors: Lisa Capodici (614) 553-3858 (614) 757-5035 ellen.barry@cardinalhealth.com lisa.capodici@cardinalhealth.com Cardinal Health Elects J. Michael Losh to its Board of Directors DUBLIN, Ohio, December 7, 2018 -Cardinal Health (NYSE: CAH), today a
Read more →-CAH
Nov 8, 2018Media: Ellen Barry Investors: Lisa Capodici (614) 553-3858 (614) 757-5035 ellen.barry@cardinalhealth.com lisa.capodici@cardinalhealth.com Cardinal Health Reports First Quarter Results for Fiscal Yea
Media: Ellen Barry Investors: Lisa Capodici (614) 553-3858 (614) 757-5035 ellen.barry@cardinalhealth.com lisa.capodici@cardinalhealth.com Cardinal Health Reports First Quarter Results for Fiscal Year 2019 DUBLIN, Ohio, November 8, 2018 - Cardinal Health (NYSE: CAH) today
Read more →-CAH
Aug 6, 2018Media: Ellen Barry Investors: Lisa Capodici (614) 553-3858 (614) 757-5035 ellen.barry@cardinalhealth.com lisa.capodici@cardinalhealth.com Cardinal Health Reports Fourth-quarter and Year-end Results
Media: Ellen Barry Investors: Lisa Capodici (614) 553-3858 (614) 757-5035 ellen.barry@cardinalhealth.com lisa.capodici@cardinalhealth.com Cardinal Health Reports Fourth-quarter and Year-end Results for Fiscal Year 2018 DUBLIN, Ohio, August 6, 2018 - Cardinal Health (NYSE
Read more →-CAH
May 3, 2018Media: Ellen Barry Investors: Lisa Capodici (614) 553-3858 (614) 757-5035 ellen.barry@cardinalhealth.com lisa.capodici@cardinalhealth.com Cardinal Health Reports Third-quarter Results for Fiscal Yea
Media: Ellen Barry Investors: Lisa Capodici (614) 553-3858 (614) 757-5035 ellen.barry@cardinalhealth.com lisa.capodici@cardinalhealth.com Cardinal Health Reports Third-quarter Results for Fiscal Year 2018 DUBLIN, Ohio, May 3, 2018 - Cardinal Health (NYSE: CAH) today repo
Read more →-CAH
Mar 8, 2018Media: Ellen Barry Investors: Lisa Capodici (614) 553-3858 (614) 757-5035 ellen.barry@cardinalhealth.com lisa.capodici@cardinalhealth.com Cardinal Health Recommends Shareholders Reject the Below-Mar
Media: Ellen Barry Investors: Lisa Capodici (614) 553-3858 (614) 757-5035 ellen.barry@cardinalhealth.com lisa.capodici@cardinalhealth.com Cardinal Health Recommends Shareholders Reject the Below-Market Mini-Tender Offer by TRC Capital Corporation DUBLIN, Ohio, Mar. 8, 2
Read more →-CAH
Feb 8, 2018Media: Ellen Barry Investors: Lisa Capodici (614) 553-3858 (614) 757-5035 ellen.barry@cardinalhealth.com lisa.capodici@cardinalhealth.com Cardinal Health Reports Second-quarter Results for Fiscal Ye
Media: Ellen Barry Investors: Lisa Capodici (614) 553-3858 (614) 757-5035 ellen.barry@cardinalhealth.com lisa.capodici@cardinalhealth.com Cardinal Health Reports Second-quarter Results for Fiscal Year 2018 DUBLIN, Ohio, Feb. 8, 2018 - Cardinal Health (NYSE: CAH) today re
Read more →-CAH
Nov 6, 2017Media: Ellen Barry Investors: Lisa Capodici (614) 553-3858 (614) 757-5035 ellen.barry@cardinalhealth.com lisa.capodici@cardinalhealth.com CARDINAL HEALTH OUTLINES LEADERSHIP SUCCESSION PLAN -- Mike
Media: Ellen Barry Investors: Lisa Capodici (614) 553-3858 (614) 757-5035 ellen.barry@cardinalhealth.com lisa.capodici@cardinalhealth.com CARDINAL HEALTH OUTLINES LEADERSHIP SUCCESSION PLAN -- Mike Kaufmann Named Chief Executive Officer, Effective January 1, 2018 -- --
Read more →-CAH
Aug 2, 2017Media: Ellen Barry Investors: Lisa Capodici (614) 553-3858 (614) 757-5035 ellen.barry@cardinalhealth.com lisa.capodici@cardinalhealth.com Cardinal Health Reports Q4 and Fiscal 2017 Results, Provides
Media: Ellen Barry Investors: Lisa Capodici (614) 553-3858 (614) 757-5035 ellen.barry@cardinalhealth.com lisa.capodici@cardinalhealth.com Cardinal Health Reports Q4 and Fiscal 2017 Results, Provides 2018 Guidance DUBLIN, Ohio, August 2, 2017 - Cardinal Health (NYSE: CAH)
Read more →-CAH
Apr 18, 2017Media: Ellen Barry (614) 553-3858 ellen.barry@cardinalhealth.com Investors: Sally Curley (614) 757-7115 sally.curley@cardinalhealth.com Cardinal Health to Acquire Leading Patient Product Portfolio f
Cardinal Health to Acquire Leading Patient Product Portfolio from Medtronic for $6.1 Billion DUBLIN, Ohio, April 18, 2017 Cardinal Health (NYSE:CAH) today announced that it has entered into a definitive agreement to acquire Medtronic s Patient Care, Deep Vein Thrombosis and Nut
Read more →-CAH
Oct 31, 2016Media: Ellen Barry Investors: Lisa Capodici (614) 553-3858 (614) 757-5035 ellen.barry@cardinalhealth.com lisa.capodici@cardinalhealth.com Cardinal Health Reports First-quarter Results for Fiscal Yea
Media: Ellen Barry Investors: Lisa Capodici (614) 553-3858 (614) 757-5035 ellen.barry@cardinalhealth.com lisa.capodici@cardinalhealth.com Cardinal Health Reports First-quarter Results for Fiscal Year 2017 DUBLIN, Ohio, Oct. 31, 2016 - Cardinal Health (NYSE: CAH) today re
Read more →-CAH
Aug 2, 2016Media: Ellen Barry Investors: Sally Curley (614) 553-3858 (614) 757-7115 ellen.barry@cardinalhealth.com sally.curley@cardinalhealth.com CARDINAL HEALTH REPORTS Q4 AND FISCAL 2016 RESULTS, PROVIDES F
Media: Ellen Barry Investors: Sally Curley (614) 553-3858 (614) 757-7115 ellen.barry@cardinalhealth.com sally.curley@cardinalhealth.com CARDINAL HEALTH REPORTS Q4 AND FISCAL 2016 RESULTS, PROVIDES FISCAL 2017 OUTLOOK DUBLIN, Ohio, Aug. 2, 2016 - Cardinal Health today re
Read more →-CAH
Apr 28, 2016Media: Debbie Mitchell Investors: Sally Curley (614) 757-6225 (614) 757-7115 debbie.mitchell@cardinalhealth.com sally.curley@cardinalhealth.com CARDINAL HEALTH REPORTS STRONG THIRD-QUARTER RESULTS F
Media: Debbie Mitchell Investors: Sally Curley (614) 757-6225 (614) 757-7115 debbie.mitchell@cardinalhealth.com sally.curley@cardinalhealth.com CARDINAL HEALTH REPORTS STRONG THIRD-QUARTER RESULTS FOR FISCAL YEAR 2016 DUBLIN, Ohio, April 28, 2016 - Cardinal Health today
Read more →-CAH
Feb 1, 2016Media: Debbie Mitchell Investors: Sally Curley (614) 757-6225 (614) 757-7115 debbie.mitchell@cardinalhealth.com sally.curley@cardinalhealth.com CARDINAL HEALTH REPORTS SECOND-QUARTER RESULTS FOR FIS
Media: Debbie Mitchell Investors: Sally Curley (614) 757-6225 (614) 757-7115 debbie.mitchell@cardinalhealth.com sally.curley@cardinalhealth.com CARDINAL HEALTH REPORTS SECOND-QUARTER RESULTS FOR FISCAL 2016 DUBLIN, Ohio, Feb. 1, 2016 - Cardinal Health today reported fisc
Read more →-CAH
Nov 2, 2015Media: Debbie Mitchell Investors: Sally Curley (614) 757-6225 (614) 757-7115 debbie.mitchell@cardinalhealth.com sally.curley@cardinalhealth.com CARDINAL HEALTH REPORTS STRONG FIRST-QUARTER RESULTS F
Media: Debbie Mitchell Investors: Sally Curley (614) 757-6225 (614) 757-7115 debbie.mitchell@cardinalhealth.com sally.curley@cardinalhealth.com CARDINAL HEALTH REPORTS STRONG FIRST-QUARTER RESULTS FOR FISCAL 2016 DUBLIN, Ohio, Nov. 2, 2015 - Cardinal Health today reporte
Read more →-CAH
Jul 30, 2015Media: Debbie Mitchell Investors: Sally Curley (614) 757-6225 (614) 757-7115 debbie.mitchell@cardinalhealth.com sally.curley@cardinalhealth.com CARDINAL HEALTH REPORTS STRONG Q4 AND RECORD FISCAL YE
Media: Debbie Mitchell Investors: Sally Curley (614) 757-6225 (614) 757-7115 debbie.mitchell@cardinalhealth.com sally.curley@cardinalhealth.com CARDINAL HEALTH REPORTS STRONG Q4 AND RECORD FISCAL YEAR-END NON-GAAP OPERATING EARNINGS RESULTS Company Points to Progress on
Read more →-CAH
Jun 5, 2015Media: Debbie Mitchell (614) 757-6225 debbie.mitchell@cardinalhealth.com Investors: Sally Curley (614) 757-7115 sally.curley@cardinalhealth.com CARDINAL HEALTH TO ACQUIRE THE HARVARD DRUG GROUP FOR
EX-99.1 2 exhibit991newsrelease.htm NEWS RELEASE Exhibit 99.1 News Release Exhibit 99.1 For Immediate Release Media: Debbie Mitchell (614) 757-6225 debbie.mitchell@cardinalhealth.com Investors: Sally Curley (614) 757-7115 sally.curley@cardinalhealth.com CARDINAL HEALTH TO ACQUIRE
Read more →-CAH
Apr 30, 2015Media: Debbie Mitchell (614) 757-6225 debbie.mitchell@cardinalhealth.com Investors: Sally Curley (614) 757-7115 sally.curley@cardinalhealth.com CARDINAL HEALTH REPORTS FISCAL 2015 THIRD-QUARTER RESU
Media: Debbie Mitchell debbie.mitchell@cardinalhealth.com Investors: Sally Curley sally.curley@cardinalhealth.com CARDINAL HEALTH REPORTS FISCAL 2015 THIRD-QUARTER RESULTS DUBLIN, Ohio, April 30, 2015 - Cardinal Health today reported fiscal year 2015 third-quarter revenue of
Read more →-CAH
Mar 2, 2015Media: Debbie Mitchell Investors: Sally Curley (614) 757-6225 (614) 757-7115 debbie.mitchell@cardinalhealth.com sally.curley@cardinalhealth.com CARDINAL HEALTH TO ACQUIRE CORDIS, A WORLDWIDE LEADER
CARDINAL HEALTH TO ACQUIRE CORDIS, A WORLDWIDE LEADER IN CARDIAC AND ENDOVASCULAR MEDICAL PRODUCTS FOR $1.944 BILLION IN CASH DUBLIN, Ohio, March 2, 2015 Cardinal Health today announced plans to acquire Johnson & Johnson s Cordis business, a leading global manufacturer of cardio
Read more →-CAH
Jan 29, 2015Media: Debbie Mitchell (614) 757-6225 debbie.mitchell@cardinalhealth.com Investors: Sally Curley (614) 757-7115 sally.curley@cardinalhealth.com CARDINAL HEALTH REPORTS FISCAL 2015 SECOND-QUARTER RES
Media: Debbie Mitchell debbie.mitchell@cardinalhealth.com Investors: Sally Curley sally.curley@cardinalhealth.com CARDINAL HEALTH REPORTS FISCAL 2015 SECOND-QUARTER RESULTS DUBLIN, Ohio, Jan. 29, 2015 - Cardinal Health today reported fiscal year 2015 second-quarter revenue o
Read more →-CAH
Oct 30, 2014Media: Debbie Mitchell (614) 757-6225 debbie.mitchell@cardinalhealth.com Investors: Sally Curley (614) 757-7115 sally.curley@cardinalhealth.com CARDINAL HEALTH REPORTS FISCAL 2015 FIRST-QUARTER RESU
Media: Debbie Mitchell debbie.mitchell@cardinalhealth.com Investors: Sally Curley sally.curley@cardinalhealth.com CARDINAL HEALTH REPORTS FISCAL 2015 FIRST-QUARTER RESULTS DUBLIN, Ohio, Oct. 30, 2014 - Cardinal Health today reported fiscal year 2015 first-quarter revenue of
Read more →-CAH
Aug 4, 2014Media: Debbie Mitchell (614) 757-6225 debbie.mitchell@cardinalhealth.com Investors: Sally Curley (614) 757-7115 sally.curley@cardinalhealth.com CARDINAL HEALTH REPORTS FOURTH-QUARTER AND FISCAL YEAR
Media: Debbie Mitchell debbie.mitchell@cardinalhealth.com Investors: Sally Curley sally.curley@cardinalhealth.com CARDINAL HEALTH REPORTS FOURTH-QUARTER AND FISCAL YEAR RESULTS, PROVIDES FISCAL 2015 OUTLOOK DUBLIN, Ohio, Aug 4, 2014 - Cardinal Health today reported earnings
Read more →-CAH
May 1, 2014Media: Debbie Mitchell (614) 757-6225 debbie.mitchell@cardinalhealth.com Investors: Sally Curley (614) 757-7115 sally.curley@cardinalhealth.com CARDINAL HEALTH REPORTS FISCAL 2014 THIRD-QUARTER RESU
Media: Debbie Mitchell debbie.mitchell@cardinalhealth.com Investors: Sally Curley sally.curley@cardinalhealth.com CARDINAL HEALTH REPORTS FISCAL 2014 THIRD-QUARTER RESULTS DUBLIN, Ohio, May 1, 2014 - Cardinal Health today reported fiscal year 2014 third-quarter revenue of $2
Read more →-CAH
Jan 30, 2014Media: Debbie Mitchell (614) 757-6225 debbie.mitchell@cardinalhealth.com Investors: Sally Curley (614) 757-7115 sally.curley@cardinalhealth.com CARDINAL HEALTH REPORTS FISCAL 2014 SECOND-QUARTER RES
Media: Debbie Mitchell debbie.mitchell@cardinalhealth.com Investors: Sally Curley sally.curley@cardinalhealth.com CARDINAL HEALTH REPORTS FISCAL 2014 SECOND-QUARTER RESULTS DUBLIN, Ohio, Jan. 30, 2014 - Cardinal Health today reported fiscal year 2014 second-quarter revenue o
Read more →Competitive Position
How CAH ranks across every disease it competes inCompetitive Position is a premium feature
See how CAH ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial